The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy.
The concerted efforts of clinicians, scientists and caregivers of HIV-infected children have led to tremendous advances in our understanding of pediatric HIV/AIDS. Antiretroviral therapy (ART; formerly known as highly active antiretroviral therapy [HAART]) has significantly extended the longevity of HIV-infected children, but there are limitations to improvements in quality of life that may persist despite therapy. ART has remarkably reduced the incidence of neurologic deficits for the majority of infected children, but some patients do not experience these benefits and children living in poorer nations, who may not have access to antiretrovirals, are particularly at risk for developing neurologic deficits. This article reviews the neurologic symptoms of pediatric HIV infection that manifest as dopaminergic disruptions and explores potential future adjuvant therapies for HIV-related neurologic disorders in children.
Webb
Katy M
KM
Behavioral Neuroscience Program, Department of Psychology, University of South Carolina, Columbia, SC 29208, USA. kwebb@med.sc.edu
Mactutus
Charles F
CF
Booze
Rosemarie M
RM
D015526:AIDS Dementia Complex / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001812:Blood-Brain Barrier; D001921:Brain / Q000254:growth & development; D017024:Chemotherapy, Adjuvant; D002648:Child; D003072:Cognition Disorders / Q000209:etiology / Q000473:pathology; D004298:Dopamine / Q000502:physiology; D006801:Humans; D008911:Minocycline / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D008911:Minocycline; D004298:Dopamine